We then confirmed the inhibitory potency of hsa‐miR‐195‐5p towards CHEK1 in ER− and ER+ breast cancer cell lines and explored the ability of specific CHEK1 inhibitors to modulate doxorubicin efficacy in vitro. Here, CHEK1 is linked to breast cancer.